CL2020000303A1 - Dihidrooxadiazinonas. - Google Patents
Dihidrooxadiazinonas.Info
- Publication number
- CL2020000303A1 CL2020000303A1 CL2020000303A CL2020000303A CL2020000303A1 CL 2020000303 A1 CL2020000303 A1 CL 2020000303A1 CL 2020000303 A CL2020000303 A CL 2020000303A CL 2020000303 A CL2020000303 A CL 2020000303A CL 2020000303 A1 CL2020000303 A1 CL 2020000303A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- preparation
- pharmaceutical compositions
- diseases
- dihydrooxadiazinones
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541627P | 2017-08-04 | 2017-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000303A1 true CL2020000303A1 (es) | 2020-11-13 |
Family
ID=63207725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000303A CL2020000303A1 (es) | 2017-08-04 | 2020-02-04 | Dihidrooxadiazinonas. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11427553B2 (enExample) |
| EP (1) | EP3661517B1 (enExample) |
| JP (2) | JP7676141B2 (enExample) |
| KR (1) | KR20200036914A (enExample) |
| CN (1) | CN111212647B (enExample) |
| AR (1) | AR112402A1 (enExample) |
| AU (1) | AU2018309356B2 (enExample) |
| BR (1) | BR112020002351A2 (enExample) |
| CA (1) | CA3071800A1 (enExample) |
| CL (1) | CL2020000303A1 (enExample) |
| CO (1) | CO2020001242A2 (enExample) |
| CR (1) | CR20200057A (enExample) |
| CU (1) | CU24608B1 (enExample) |
| EA (1) | EA202090448A1 (enExample) |
| EC (1) | ECSP20008441A (enExample) |
| IL (1) | IL272098B2 (enExample) |
| JO (1) | JOP20200024A1 (enExample) |
| MA (1) | MA49750A (enExample) |
| MX (1) | MX2020001404A (enExample) |
| PE (1) | PE20200936A1 (enExample) |
| PH (1) | PH12020500134A1 (enExample) |
| SG (1) | SG11201913775UA (enExample) |
| TW (1) | TWI791581B (enExample) |
| UA (1) | UA125731C2 (enExample) |
| UY (1) | UY37832A (enExample) |
| WO (1) | WO2019025562A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| EP3661917B1 (en) | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| TW202031677A (zh) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
| WO2020157188A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones for the treatment of hyperproliferative diseases |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
| CN117279644A (zh) | 2021-03-03 | 2023-12-22 | 拜耳股份有限公司 | 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 |
| EP4289828A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one |
| EP4289829A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one |
| CN120187704A (zh) * | 2022-11-24 | 2025-06-20 | 盛睿泽华医药科技（苏州）有限公司 | 吡啶酮化合物及其制备方法和用途 |
| CN117903077B (zh) * | 2023-01-13 | 2024-09-03 | 上海超阳药业有限公司 | 二氢噁二嗪酮化合物及其应用 |
| CN118420559B (zh) * | 2023-04-27 | 2025-02-14 | 上海超阳药业有限公司 | 氘代噁二嗪酮化合物及其用途 |
| CN118047833B (zh) * | 2024-01-31 | 2025-03-14 | 海南大学 | 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097671A (en) * | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4258094A (en) * | 1979-04-26 | 1981-03-24 | Brunswick Corporation | Melt bonded fabrics and a method for their production |
| US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
| DE3172252D1 (en) | 1980-11-14 | 1985-10-17 | Ici Plc | Heterocyclic compounds |
| DE3263497D1 (en) | 1981-03-04 | 1985-06-20 | Ciba Geigy Ag | Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use |
| ZA827641B (en) | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
| US4495185A (en) | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
| US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
| JPS59196874A (ja) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | トリアジン誘導体 |
| JPS6153270A (ja) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| DE3677316D1 (de) | 1985-10-17 | 1991-03-07 | Smith Kline French Lab | 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate. |
| EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
| ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| JPH0676325B2 (ja) * | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | オキサジアジン誘導体を有効成分として含有する抗血栓剤 |
| JPH07508987A (ja) | 1992-07-01 | 1995-10-05 | オーソ・フアーマシユーチカル・コーポレーシヨン | １−アリールスルホニル，アリールカルボニルおよび１−アリールホスホニル−３−フェニル−１，４，５，６−テトラヒドロピリダジン |
| JPH07291968A (ja) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | トリアジノン誘導体またはその塩類 |
| DE19929787A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
| EP1368035A1 (en) * | 2001-02-12 | 2003-12-10 | MERCK PATENT GmbH | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| WO2008108602A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
| US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
| CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5794297B2 (ja) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９アゴニストとしてのピリダジノン |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2014164704A2 (en) | 2013-03-11 | 2014-10-09 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| WO2017027854A1 (en) * | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for cancer expressing pde3a or slfn12 |
| US10729680B2 (en) | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| TW201733591A (zh) | 2016-02-05 | 2017-10-01 | 拜耳製藥公司 | 用於癌症病人分級及癌症治療之化合物、組合物及方法 |
| KR101831772B1 (ko) * | 2016-03-24 | 2018-03-06 | 아이디에스(주) | 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| EP3661917B1 (en) | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| TW202031677A (zh) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
-
2018
- 2018-08-01 JO JOP/2020/0024A patent/JOP20200024A1/ar unknown
- 2018-08-02 EP EP18755153.6A patent/EP3661517B1/en active Active
- 2018-08-02 AU AU2018309356A patent/AU2018309356B2/en not_active Ceased
- 2018-08-02 UA UAA202001558A patent/UA125731C2/uk unknown
- 2018-08-02 BR BR112020002351-5A patent/BR112020002351A2/pt not_active IP Right Cessation
- 2018-08-02 SG SG11201913775UA patent/SG11201913775UA/en unknown
- 2018-08-02 EA EA202090448A patent/EA202090448A1/ru unknown
- 2018-08-02 CN CN201880050751.0A patent/CN111212647B/zh active Active
- 2018-08-02 KR KR1020207005998A patent/KR20200036914A/ko not_active Withdrawn
- 2018-08-02 CA CA3071800A patent/CA3071800A1/en active Pending
- 2018-08-02 WO PCT/EP2018/071039 patent/WO2019025562A1/en not_active Ceased
- 2018-08-02 JP JP2020505898A patent/JP7676141B2/ja active Active
- 2018-08-02 CU CU2020000008A patent/CU24608B1/es unknown
- 2018-08-02 MX MX2020001404A patent/MX2020001404A/es unknown
- 2018-08-02 PE PE2020000184A patent/PE20200936A1/es unknown
- 2018-08-02 MA MA049750A patent/MA49750A/fr unknown
- 2018-08-02 US US16/635,504 patent/US11427553B2/en active Active
- 2018-08-02 CR CR20200057A patent/CR20200057A/es unknown
- 2018-08-03 TW TW107127172A patent/TWI791581B/zh not_active IP Right Cessation
- 2018-08-03 AR ARP180102218 patent/AR112402A1/es not_active Application Discontinuation
- 2018-08-03 UY UY0001037832A patent/UY37832A/es not_active Application Discontinuation
-
2020
- 2020-01-16 IL IL272098A patent/IL272098B2/en unknown
- 2020-01-17 PH PH12020500134A patent/PH12020500134A1/en unknown
- 2020-02-04 CL CL2020000303A patent/CL2020000303A1/es unknown
- 2020-02-04 EC ECSENADI20208441A patent/ECSP20008441A/es unknown
- 2020-02-04 CO CONC2020/0001242A patent/CO2020001242A2/es unknown
-
2022
- 2022-07-11 US US17/862,255 patent/US12258323B2/en active Active
- 2022-07-14 US US17/865,236 patent/US11773070B2/en active Active
-
2023
- 2023-06-13 JP JP2023097166A patent/JP2023115065A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20008441A (es) | Dihidrooxadiazinonas | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| DOP2018000226A (es) | Nuevos derivados de pirazolopirimidina | |
| CO2019014484A2 (es) | Nuevos derivados de azaquinolina | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| CO2020013876A2 (es) | Nuevos derivados de quinolina | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| DOP2019000206A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| UY38816A (es) | Nuevos derivados de isoquinolina | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol |